FDA approves Bayer's Ambelvist, a lower-dose gadolinium MRI contrast agent
The approval rests on Phase 3 QUANTI data showing lesion visualization at 0.01 mmol/kg comparable to existing agents dosed at twice to five times the gadolinium load.
Executive Summary
- The FDA granted full approval to Bayer's new gadolinium-based MRI contrast agent, resolving a Phase 3 registrational program that completed enrollment on schedule two years earlier.
- The approved agent carries the lowest gadolinium dose among macrocyclic contrast agents on the U.S. market, while pivotal data showed lesion visualization comparable to agents dosed several times higher.
- The approval lands in a mature, low-novelty contrast-agent category with no unresolved mechanism question; the competitive test is dose and tolerability, not efficacy against a validated standard.
- The label carries a boxed warning tied to the drug class, and how postmarketing obligations and adoption against entrenched agents play out remains the open commercial question.
The decision
The FDA approved Ambelvist (gadoquatrane) for use with contrast-enhanced MRI to detect and visualize lesions with abnormal vascularity in the central nervous system and non-CNS body regions, covering adults and pediatric patients including term neonates, Bayer said. The approval rests on the global pivotal Phase 3 QUANTI studies, run under NCT05915728 among others, a randomized, quadruple-masked, 404-patient trial comparing gadoquatrane against an already available macrocyclic gadolinium-based contrast agent. The trial completed in June 2024, and the approval followed roughly two years later. Bayer’s+1Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body RegionsJun 15, 2026A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)NCT05915728
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What it delivers
Ambelvist's approved dose is 0.01 mmol/kg of body weight, delivering 0.04 mmol Gd/kg, which Bayer said represents 60% less gadolinium than agents dosed at 0.1 mmol Gd/kg and 20% less than gadopiclenol at its 0.05 mmol Gd/kg dose. In the QUANTI studies, blinded independent readers found that visualization scores and the number of lesions identified with gadoquatrane at that lower dose were similar to other tested macrocyclic agents dosed higher, in descriptive analyses comparing combined pre- and post-contrast image sets against unenhanced MRI. Pediatric use is supported by pharmacokinetic and safety data from 93 children aged 28 days to under 18 years who received a single 0.01 mmol/kg dose. Bayer’sBayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body RegionsJun 15, 2026
Safety carryover
Ambelvist carries a boxed warning covering risks tied to intrathecal administration and nephrogenic systemic fibrosis, a class-level risk associated with gadolinium-based contrast agents, and it is contraindicated in patients with a history of severe hypersensitivity to the agent. The label also carries warnings for hypersensitivity reactions, gadolinium retention, acute kidney injury, and interference with lesion visualization. Dr. Christopher Hancock, an investigator on the QUANTI studies and director of neuroradiology at HALO Diagnostics Desert Cities, said the approval provides "an additional option that can help deliver contrast-enhanced images at the lowest macrocyclic GBCA dose, reducing gadolinium exposure while preserving the clinical information we often need". Bayer’sBayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body RegionsJun 15, 2026
The field it enters
Contrast-enhanced MRI agents are a mature category: the competitive set surrounding this approval includes other macrocyclic gadolinium agents such as Bayer's own gadopentetate dimeglumine, along with iodinated and small-molecule agents like iopamidol, gadoterate meglumine, and iohexol used across diagnostic imaging more broadly. None of these represents an open efficacy question the way an unproven disease-modifying mechanism would; the competitive test here is dose, tolerability, and radiologist preference among agents whose visualization performance is already established. Bayer, whose overall trial completion rate stands at 92% across 1,086 tracked programs, has run macrocyclic contrast-agent development since the class emerged.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.